Furuta Masaya, Nozaki Miwako, Kawashima Miho, Iimuro Mamoru, Kitazumi Yoshinori, Okayama Aya, Natsui Satoshi, Hamashima Yoshio, Nagao Koushuu
Department of Radiology, Koshigaya Hospital, Dokkyo University School of Medicine, 2-1-50 Minami-Koshigaya, 343-8555, Koshigaya, Japan.
Eur J Nucl Med Mol Imaging. 2003 Jul;30(7):982-7. doi: 10.1007/s00259-003-1188-z. Epub 2003 May 7.
After radiation therapy of lung cancer, a dense fibrotic shadow develops in the irradiated lung. Owing to this fibrosis, early detection of local recurrence after treatment is sometimes difficult even when using computed tomography (CT) and magnetic resonance imaging. We investigated the diagnostic accuracy of technetium-99m hexakis 2-methoxyisobutylisonitrile ((99m)Tc-MIBI) scintigraphy for the detection of recurrent lung cancer following definitive radiation therapy. Eighteen patients with primary non-small cell lung cancer treated with radiation therapy 1 year previously were studied with (99m)Tc-MIBI scintigraphy. They showed no evidence of local recurrence on serial chest radiographs. All single-photon emission tomography (SPET) images acquired 2 h after intravenous administration of the radiopharmaceutical were visually interpreted with knowledge of the pretreatment chest radiograph, CT and the details of radiation therapy (radiation portals and administered doses). A region of interest (ROI) analysis was also performed. In addition to the ROI ratio of tumour uptake to accumulation in contralateral normal lung (tumour/lung ratio), another semiquantitative analysis, the ratio of tumour uptake to accumulation in radiation fibrosis (tumour/fibrosis ratio), was performed to differentiate between accumulation in radiation fibrosis and the tumour uptake. The scintigraphic diagnoses were correlated with clinical outcome. The sensitivity, specificity and negative predictive value of (99m)Tc-MIBI scintigraphy for the detection of recurrent lung cancer were all 88.9% (8/9). The tumour/lung ratios (mean+/-SEM) of the nine patients with local recurrence and the other eight without local failure were 2.00+/-0.11 and 1.40+/-0.09, respectively ( P<0.01). The tumour/fibrosis ratios of the patients with and those without recurrence were 1.47+/-0.08 and 0.93+/-0.05, respectively ( P<0.01). These results suggest that (99m)Tc-MIBI scintigraphy might be of value for the detection of recurrent lung cancer, and especially of small foci in areas of radiation fibrosis that are hardly noticeable on serial chest radiographs.
肺癌放疗后,受照射的肺部会出现致密的纤维化阴影。由于这种纤维化,即使使用计算机断层扫描(CT)和磁共振成像,治疗后局部复发的早期检测有时也很困难。我们研究了锝-99m 六甲基异丁基异腈((99m)Tc-MIBI)闪烁显像对确定性放疗后复发性肺癌的诊断准确性。对18例1年前接受放疗的原发性非小细胞肺癌患者进行了(99m)Tc-MIBI闪烁显像研究。他们的系列胸部X线片未显示局部复发迹象。在了解治疗前胸部X线片、CT和放疗细节(放疗野和给予剂量)的情况下,对静脉注射放射性药物2小时后采集的所有单光子发射断层扫描(SPET)图像进行视觉解读。还进行了感兴趣区(ROI)分析。除了肿瘤摄取与对侧正常肺内积聚的ROI比值(肿瘤/肺比值)外,还进行了另一种半定量分析,即肿瘤摄取与放射性纤维化内积聚的比值(肿瘤/纤维化比值),以区分放射性纤维化内的积聚和肿瘤摄取。闪烁显像诊断与临床结果相关。(99m)Tc-MIBI闪烁显像检测复发性肺癌的敏感性、特异性和阴性预测值均为88.9%(8/9)。9例局部复发患者和其他8例无局部复发患者的肿瘤/肺比值(平均值±标准误)分别为2.00±0.11和1.40±0.09(P<0.01)。复发患者和未复发患者的肿瘤/纤维化比值分别为1.47±0.08和0.93±0.05(P<0.01)。这些结果表明,(99m)Tc-MIBI闪烁显像可能对复发性肺癌的检测有价值,尤其是对系列胸部X线片上难以察觉的放射性纤维化区域内的小病灶。